RSS-Feed abonnieren
DOI: 10.1055/s-0038-1660797
Hepatorenal Syndrome: Physiology, Diagnosis and Management
Publikationsverlauf
Publikationsdatum:
06. August 2018 (online)
![](https://www.thieme-connect.de/media/sir/201803/lookinside/thumbnails/10-1055-s-0038-1660797_001075-1.jpg)
Abstract
Individuals with end-stage liver disease are susceptible to a myriad of highly morbid complications, including hepatorenal syndrome (HRS). This specific type of renal dysfunction in patients with underlying liver disease occurs in pathophysiologically normal kidneys and is a result of renal vasoconstriction secondary to diminished renal blood flow in the setting of worsening hepatic dysfunction. Liver transplantation is curative; shortage of available organs limits access to this beneficial therapy. Medical management of HRS has demonstrated increasing promise. Transjugular intrahepatic portosystemic shunt creation has also been shown to be efficacious in enhancing transplant-free survival, although further study is advisable before widespread implementation of this strategy.
-
References
- 1 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362 (9398): 1819-1827
- 2 Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8 (05) 1151-1157
- 3 Epstein M. Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol 1994; 4 (10) 1735-1753
- 4 Fernandez-Seara J, Prieto J, Quiroga J. , et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97 (05) 1304-1312
- 5 Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1 (05) 1066-1079
- 6 Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol 2015; 30 (02) 236-243
- 7 Oliver JA, Verna EC. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Kidney Int 2010; 77 (08) 669-680
- 8 Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969; 280 (25) 1367-1371
- 9 Angeli P, Ginès P, Wong F. , et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62 (04) 968-974
- 10 Sanyal AJ, Boyer TD, Frederick RT. , et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther 2017; 45 (11) 1390-1402
- 11 Singh V, Ghosh S, Singh B. , et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56 (06) 1293-1298
- 12 Cavallin M, Kamath PS, Merli M. , et al; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015; 62 (02) 567-574
- 13 Guevara M, Ginès P, Bandi JC. , et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28 (02) 416-422
- 14 Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis 2018; 50 (04) 323-330
- 15 Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20 (10) 2704-2714
- 16 Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995; 17 (02) 135-146
- 17 Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 1977; 8 (01) 287-292
- 18 Baraldi O, Valentini C, Donati G. , et al. Hepatorenal syndrome: update on diagnosis and treatment. World J Nephrol 2015; 4 (05) 511-520
- 19 Lee JP, Heo NJ, Joo KW. , et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 2010; 25 (08) 2772-2785
- 20 Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21 (02) 478-482
- 21 Boyle G. Simultaneous Liver Kidney (SLK) Allocation Policy. Rockville, MD: Department of Health and Human Services, OUKTC; 2016